The global 3D laparoscopy imaging systems market was surpassed at USD 3.98 billion in 2021 and is expected to hit around USD 6.5 billion by 2030, growing at a CAGR of 5.6% from 2022 to 2030.
The question is no longer confined as to how quickly 3D laparoscopy imaging systems will overtake 2D systems; it is how 3D will lead and grab opportunities from invasive surgeries and aid surgeons bundle a patient-centric offering. As patients leading demanding lifestyles tend to prefer minimally-invasive procedures, manufacturers will enjoy better penetration of 3D laparoscopy imaging systems.
Growth of the market will also gain momentum owing to the rising number of bariatric surgeries being performed. As surgeons require a stereoscopic vision of anatomy for an accurate dissection prior to the surgery, the application scope of 3D laparoscopy imaging systems is likely to expand in bariatric surgeries. However, amidst the steady growth of the industry, challenges from technologically-driven 3D laparoscopy imaging systems flag the affordability issue, which is likely to crop up, especially in the developing countries.
To put this in perspective, 'high cost' can limit the growth of the landscape, and it will become a deciding factor for the shift from 2D to 3D laparoscopy imaging systems. Overall, the industry will progress at a compound annual growth rate of 5.6 percent during the forecast period of 2022-2030.
Scope of The Report
Report Coverage | Details |
Market Size in 2021 | USD 3.98 billion |
Revenue Forecast by 2030 | USD 6.5 billion |
Growth rate from 2022 to 2030 | CAGR of 5.6% |
Base Year | 2021 |
Forecast Period | 2022 to 2030 |
Segmentation | Type of Treatment, End User, Region |
Companies Covered | Olympus Corporation, KARL STORZ SE & Co. KG, B. Braun Melsungen AG, CONMED Corporation, Visionsense, Richard Wolf GmbH, Fujifilm Holdings Corporation, Sometech, Inc. |
2D to 3D - The Shift is Underway
As the healthcare industry harnesses the power of technology to develop patient-centric treatment options, 3D laparoscopy imaging systems will dim the market value of 2D systems. 3D laparoscopy imaging systems offer enhanced operative vision with a binocular-depth perception that is absent in 2D laparoscopy imaging systems. Growth in the number of surgeries using advanced laparoscopy imaging systems is further increasing the reliance of surgeons on these units, given their better performance and lower error rates.
Beside surgeons, 3D laparoscopic procedures also gain the favorability of patients. Patients show a high proclivity for minimally-invasive procedures, given their emphasis on less blood loss, smaller scars, reduced pain, better recovery times, and shorter stay, which is likely to uptake the demand for 3D laparoscopy imaging systems during the forecast period.
Inpatient to Outpatient Settings - A Notable Shift to Focus On
Unsurprisingly, hospitals hold a leading stance in the 3D laparoscopy imaging systems market, on account of discretionary spending by government bodies in the form of grants for innovation in medical devices and establishment of new hospitals. The adoption of 3D laparoscopy imaging systems at a CAGR of ~ 6.3% in hospitals during the forecast period represents the traditional preference for inpatient settings; however, as ambulatory surgical centers and clinics bank big on minimal wait times, easy scheduling, affordability, and better recovery times, outpatient settings are likely to grow in terms of popularity, in the future, for various surgeries.
The deployment of 3D laparoscopy imaging systems will remain high for bariatric surgeries, which is gaining popularity among the obese and diabetic populace. Bariatric surgeries remain a key revenue pocket for the 3D laparoscopy imaging systems market, currently holding a share of ~ 35.1 percent, and increasing its revenue share at an exponential rate.
New dimensions to 3D laparoscopy imaging systems are likely to emerge from gynecological surgeries, as gynecologists seek extended range of motion and improved hand-eye coordination. Currently, gynecological surgeries account for ~ 29.8 percent of the global sales of 3D laparoscopy imaging systems, and this segment is likely to grow at a CAGR of ~ 5.5 percent during the forecast period, as patients are drawn towards technologically-advanced healthcare procedures for better outcomes.
Will Robotic Systems Ambush Market Growth?
As the healthcare industry looks at the technology that blurs the boundary separating near-accurate and accurate surgeries, the rise of robotic systems will play a central role. A high level of dexterity with improved movement as compared to a human hand or wrist has been the key distinguishing proposition for robotic systems, thereby paling the popularity of 3D laparoscopy imaging systems.
Should market players worry about this?
The answer is - No. Though robotic systems are deemed efficient with a low risk of infection and blood loss, 3D laparoscopy imaging systems tend to outperform these systems in selected procedures, such as mitral valve repair and keyhole surgeries. Robotic procedures require more operative time as compared to 3D laparoscopy imaging systems. For instance, robotic procedures take around 224 minutes for a mitral valve repair surgery, while the same can be performed using laparoscopic systems in 180 minutes, with lesser blood transfusion. In addition, market players can renew the interest of surgeons in 3D laparoscopy imaging systems by employing a price-competitive strategy to regain the paling strength of the market, as the price of robotic systems is on the higher side.
Interpreting the 3D Laparoscopy Imaging Systems Landscape for Market Players
High demand, strong portfolio, solid R&D spending, and positive legislative environment account for the high-value growth of the European 3D laparoscopy imaging systems market. Germany - being the leading medical device market in Europe in terms of revenue, holds enormous potential, with an anticipated value of ~ US$ 404 million by 2030.
The incorporation of new technologies and investments towards increasing production capacity will remain the common thread across manufacturing capabilities across the country. For example, a German player, KARL STORZ SE & Co. KG, announced the introduction of hyperspectral imaging in its range of products, in June 2019. Another player, B. Braun Melsungen AG, inaugurated 5 new medical production facilities in Penang, Malaysia, well-equipped with advanced technology and production infrastructure to manufacture medical devices for pharmaceutical solutions, infusion therapy, and surgical instruments.
With a promising future, the 3D laparoscopy imaging systems market does hold underlying possibilities and opportunities for prominent and new entrants to outscore the performance of established players. Manufacturers should look at the expansion of their product portfolio, coupled with focus on broadening their exposure in developing countries by recruiting direct sales force professionals. Investments made toward the integration of advanced technologies for the development of minimally-invasive devices will remain well-appreciated by surgeons and patients. Building partnerships with hospitals and ambulatory surgery centers will help manufacturers gain a revenue influx in the long-term, and help sustain their position in the 3D laparoscopy imaging systems market.
Global 3D Laparoscopy Imaging Systems Market: Overview
3D laparoscopic imaging systems have stereoscopic vision, where depth perception is achieved by different unique images received by each eye. Recent improvements in stereoscopic projection technology using passive polarizing displays have significantly improved novice surgeon performance during the acquisition of minimally-invasive surgical skills.
Strategic Acquisitions and Partnerships Drive 3D Laparoscopy Imaging Systems Market
Technological Advances in Surgical Visualization to Propel 3D Laparoscopy Imaging Systems Market
Rise in Scope of 3D Laparoscopy in Bariatric Surgery
North America a Prominent 3D Laparoscopy Imaging Systems Market
Key Players
Market Segmentation
By Type of Treatment
By End User
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on 3D Laparoscopy Imaging Systems Market
5.1. COVID-19 Landscape: 3D Laparoscopy Imaging Systems Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global 3D Laparoscopy Imaging Systems Market, By Type of Treatment
8.1. 3D Laparoscopy Imaging Systems Market, by Type of Treatment, 2022-2030
8.1.1. Pharmacological Therapies
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Surgeries
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global 3D Laparoscopy Imaging Systems Market, By End User
9.1. 3D Laparoscopy Imaging Systems Market, by End User, 2022-2030
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Ambulatory Surgical Centers
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Specialty Clinics
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global 3D Laparoscopy Imaging Systems Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.1.2. Market Revenue and Forecast, by End User (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.1.3.2. Market Revenue and Forecast, by End User (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.1.4.2. Market Revenue and Forecast, by End User (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.2.2. Market Revenue and Forecast, by End User (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.2.3.2. Market Revenue and Forecast, by End User (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.2.4.2. Market Revenue and Forecast, by End User (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.2.5.2. Market Revenue and Forecast, by End User (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.2.6.2. Market Revenue and Forecast, by End User (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.3.2. Market Revenue and Forecast, by End User (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.3.3.2. Market Revenue and Forecast, by End User (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.3.4.2. Market Revenue and Forecast, by End User (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.3.5.2. Market Revenue and Forecast, by End User (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.3.6.2. Market Revenue and Forecast, by End User (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.4.2. Market Revenue and Forecast, by End User (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.4.3.2. Market Revenue and Forecast, by End User (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.4.4.2. Market Revenue and Forecast, by End User (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.4.5.2. Market Revenue and Forecast, by End User (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.4.6.2. Market Revenue and Forecast, by End User (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.5.2. Market Revenue and Forecast, by End User (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.5.3.2. Market Revenue and Forecast, by End User (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Type of Treatment (2017-2030)
10.5.4.2. Market Revenue and Forecast, by End User (2017-2030)
Chapter 11. Company Profiles
11.1. Olympus Corporation
11.1.1. Company Overview
11.1.2. Type of Treatment Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. KARL STORZ SE & Co. KG
11.2.1. Company Overview
11.2.2. Type of Treatment Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. B. Braun Melsungen AG
11.3.1. Company Overview
11.3.2. Type of Treatment Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. CONMED Corporation
11.4.1. Company Overview
11.4.2. Type of Treatment Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Visionsense
11.5.1. Company Overview
11.5.2. Type of Treatment Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Richard Wolf GmbH
11.6.1. Company Overview
11.6.2. Type of Treatment Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Fujifilm Holdings Corporation
11.7.1. Company Overview
11.7.2. Type of Treatment Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Sometech, Inc.
11.8.1. Company Overview
11.8.2. Type of Treatment Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms